Nail Psoriasis: A Review of Treatment Options

[1]  G. Keating.  Apremilast: A Review in Psoriasis and Psoriatic Arthritis , 2017, Drugs.

[2]  G. Girolomoni,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) , 2015, The British journal of dermatology.

[3]  A. Menter,et al.  Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  A. Wojas-Pelc,et al.  Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis , 2015, Postepy dermatologii i alergologii.

[5]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[6]  L. See,et al.  A Chinese Herb, Indigo Naturalis, Extracted in Oil (Lindioil) Used Topically to Treat Psoriatic Nails: A Randomized Clinical Trial. , 2015, JAMA dermatology.

[7]  M. Sundaram,et al.  Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  M. Pasch,et al.  Nail Psoriasis, the unknown burden of disease , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  A. Gottlieb,et al.  Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  K. Reich,et al.  Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis , 2014, The British journal of dermatology.

[11]  V. Sehgal,et al.  Anthralin/dithranol in dermatology , 2014, International journal of dermatology.

[12]  P. C. van de Kerkhof,et al.  The Impact of Fingernail Psoriasis on Patients' Health-Related and Disease-Specific Quality of Life , 2014, Dermatology.

[13]  B. Elewski,et al.  A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone diproprionate ointment (64 mg/g) in patients with nail psoriasis. , 2014, Journal of drugs in dermatology : JDD.

[14]  L. See,et al.  Efficacy and safety of Indigo naturalis extract in oil (Lindioil) in treating nail psoriasis: a randomized, observer-blind, vehicle-controlled trial. , 2014, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[15]  P. V. D. van de Kerkhof,et al.  Scoring nail psoriasis. , 2014, Journal of the American Academy of Dermatology.

[16]  S. Dogra,et al.  Acitretin in psoriasis: an evolving scenario , 2014, International journal of dermatology.

[17]  M. Pasch,et al.  The prevalence of onychomycosis in psoriatic patients: a systematic review , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  H. Nakagawa,et al.  Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes , 2014, The British journal of dermatology.

[19]  Y. Wasfi,et al.  Ustekinumab improves nail disease in patients with moderate‐to‐severe psoriasis: results from PHOENIX 1 , 2014, The British journal of dermatology.

[20]  W. Liao,et al.  Genetic Epidemiology of Psoriasis , 2014, Current Dermatology Reports.

[21]  V. Richer,et al.  Treatment of Nail Psoriasis with Intralesional Triamcinolone Acetonide Using a Needle-Free Jet Injector: A Prospective Trial , 2014, Journal of cutaneous medicine and surgery.

[22]  A. Patrizi,et al.  A 36‐week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[23]  M. Goldust,et al.  Clinical Trial Study in the Treatment of Nail Psoriasis with Pulsed Dye Laser. , 2013, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[24]  A. H. Erbil,et al.  Treatment of nail psoriasis with tumor necrosis factor‐alpha blocker agents: An open‐label, unblinded, comparative study , 2013, The Journal of dermatology.

[25]  A. Aktürk,et al.  Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. , 2013, Journal of drugs in dermatology : JDD.

[26]  D. M. van der Heijde,et al.  Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) , 2013, Annals of the rheumatic diseases.

[27]  M. Pasch,et al.  Nail psoriasis: a questionnaire‐based survey , 2013 .

[28]  M. D’Agostino,et al.  Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open‐label study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[29]  J. Krueger,et al.  IL-17 targeted therapies for psoriasis , 2013, Expert opinion on investigational drugs.

[30]  Y. Poulin,et al.  Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[31]  D. Sotiriadis,et al.  Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study , 2013, The Journal of dermatological treatment.

[32]  A. Kyrgidis,et al.  Re‐evaluation of the risk for major adverse cardiovascular events in patients treated with anti‐IL‐12/23 biological agents for chronic plaque psoriasis: a meta‐analysis of randomized controlled trials , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[33]  E. Berardesca,et al.  A 24‐week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis , 2013, The British journal of dermatology.

[34]  Ahmed Al-Mutairi,et al.  Nail Psoriasis Treated with Pulse Dye Laser , 2013, Indian journal of dermatology.

[35]  N. Al‐Mutairi,et al.  Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab , 2013, Expert opinion on biological therapy.

[36]  D. Sotiriadis,et al.  Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study , 2013, The Journal of dermatological treatment.

[37]  S. Chimenti,et al.  TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis , 2013, Expert opinion on biological therapy.

[38]  A. Tosti,et al.  Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients , 2013, International journal of dermatology.

[39]  K. Pavelka,et al.  Leflunomide in psoriatic arthritis: Results from a large European prospective observational study , 2013, Arthritis care & research.

[40]  Yu-Chen Huang,et al.  Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: A single‐blind, intrapatient left‐to‐right controlled study , 2013, Lasers in surgery and medicine.

[41]  K. Papp,et al.  Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study , 2013, The British journal of dermatology.

[42]  M. Lebwohl,et al.  Interventions for nail psoriasis. , 2013, The Cochrane database of systematic reviews.

[43]  P. C. van de Kerkhof,et al.  Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. , 2012, European journal of dermatology : EJD.

[44]  P. Spuls,et al.  Brodalumab and ixekizumab, anti‐interleukin‐17‐receptor antibodies for psoriasis: a critical appraisal , 2012, The British journal of dermatology.

[45]  J. Ortonne,et al.  Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study , 2012, The British journal of dermatology.

[46]  Mahboob Rahman,et al.  Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. , 2012, Arthritis and rheumatism.

[47]  Jashin J. Wu.  Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. , 2012, The New England journal of medicine.

[48]  M. Sánchez-Regaña,et al.  Efficacy of adalimumab in the treatment of psoriasis: A retrospective study of 15 patients in daily practice , 2012, The Journal of dermatological treatment.

[49]  K. Chanprapaph,et al.  The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study. , 2012, Journal of the American Academy of Dermatology.

[50]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[51]  H. Nakagawa,et al.  Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab , 2012, The Journal of dermatology.

[52]  R. Nakamura,et al.  Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. , 2012, Anais brasileiros de dermatologia.

[53]  H. Nakagawa,et al.  Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial , 2012, The Journal of dermatology.

[54]  D. Rigopoulos,et al.  Efficacy of Ustekinumab in Nail Psoriasis and Improvement in Nail-Associated Quality of Life in a Population Treated with Ustekinumab for Cutaneous Psoriasis: An Open Prospective Unblinded Study , 2011, Dermatology.

[55]  L. See,et al.  Treatment of Psoriatic Nails with Indigo Naturalis Oil Extract: A Non-Controlled Pilot Study , 2011, Dermatology.

[56]  P. Sfikakis,et al.  Adalimumab or Cyclosporine as Monotherapy and in Combination in Severe Psoriatic Arthritis: Results from a Prospective 12-month Nonrandomized Unblinded Clinical Trial , 2011, The Journal of Rheumatology.

[57]  J. Ortonne,et al.  A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. , 2011, The New England journal of medicine.

[58]  S. Bodur,et al.  Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one‐blind, randomized study , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[59]  G. Safa,et al.  Dramatic Response of Nail Psoriasis to Infliximab , 2011, Case reports in medicine.

[60]  M. Alsina-Gibert,et al.  Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy) , 2011 .

[61]  T. Lotti,et al.  Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[62]  H. Nakagawa,et al.  Long‐term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma , 2011, The Journal of dermatology.

[63]  M. Lebwohl,et al.  UV-A and UV-B penetration of normal human cadaveric fingernail plate. , 2011, Archives of dermatology.

[64]  K. Papp,et al.  Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. , 2011, Archives of dermatology.

[65]  H. Turan,et al.  Nail Psoriasis Successfully Treated with Intralesional Methotrexate: Case Report , 2011, Dermatology.

[66]  E. Rallis,et al.  Ustekinumab for rapid treatment of nail psoriasis. , 2010, Archives of dermatology.

[67]  J. Saurat,et al.  A phase IIIb, multicentre, randomized, double‐blind, vehicle‐controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study , 2010, The British journal of dermatology.

[68]  K. Katsuoka,et al.  Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index , 2010, International journal of dermatology.

[69]  J. Saurat,et al.  Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial , 2010, Dermatology.

[70]  H. Nakagawa,et al.  Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. , 2010, Journal of dermatological science.

[71]  H. Kupper,et al.  Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy , 2010, Arthritis research & therapy.

[72]  A. Katsambas,et al.  Treatment of nail psoriasis with adalimumab: an open label unblinded study , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[73]  Y. Oram,et al.  Pulsed Dye Laser in the Treatment of Nail Psoriasis , 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[74]  F. Nestle,et al.  Progress in understanding the immunopathogenesis of psoriasis. , 2009, Actas dermo-sifiliograficas.

[75]  N. Irla,et al.  Marked Improvement in Nail Psoriasis during Treatment with Adalimumab , 2009, Dermatology.

[76]  P. Goupille,et al.  Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions , 2009, Annals of the rheumatic diseases.

[77]  J. Lambert,et al.  Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate‐to‐severe psoriasis , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[78]  P. Jaen,et al.  Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[79]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[80]  D. Gladman,et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.

[81]  Andrea W. M. Evers,et al.  β-Defensin-2 Protein Is a Serum Biomarker for Disease Activity in Psoriasis and Reaches Biologically Relevant Concentrations in Lesional Skin , 2009, PloS one.

[82]  B. Piraccini,et al.  Evaluation of the efficacy of acitretin therapy for nail psoriasis. , 2009, Archives of dermatology.

[83]  D. Berker.  Management of psoriatic nail disease. , 2009 .

[84]  C. R. Daniel,et al.  Treatment of Nail Psoriasis with a Two-Compound Formulation of Calcipotriol plus Betamethasone Dipropionate Ointment , 2009, Dermatology.

[85]  Gonçalo Abecasis,et al.  Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis , 2009, Nature Genetics.

[86]  Shu-Chen Chang,et al.  Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. , 2008, Archives of dermatology.

[87]  M. Mendiola,et al.  Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. , 2008, European journal of dermatology : EJD.

[88]  G. Márquez Balbás,et al.  Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[89]  C. Owen,et al.  Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients , 2008, Clinical and experimental dermatology.

[90]  E. Rallis,et al.  Rapid response of nail psoriasis to etanercept. , 2008, The Journal of rheumatology.

[91]  W. Azim,et al.  Treatment of nail psoriasis with a modified regimen of steroid injections. , 2008, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[92]  F. Nestle,et al.  Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. , 2008, Journal of the American Academy of Dermatology.

[93]  A. Prins,et al.  Instability of Topical Ciclosporin Emulsion for Nail Psoriasis , 2007, Dermatology.

[94]  D. Sasseville,et al.  Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. , 2007, Journal of the American Academy of Dermatology.

[95]  O. Ishikawa,et al.  Successful treatment of psoriatic nails with low-dose cyclosporine administration. , 2007, European journal of dermatology : EJD.

[96]  S. Chimenti,et al.  Childhood Nail Psoriasis: A Useful Treatment with Tazarotene 0.05% , 2007, Pediatric dermatology.

[97]  J. Callen.  Complications and adverse reactions in the use of newer biologic agents. , 2007, Seminars in cutaneous medicine and surgery.

[98]  I. Dobrić,et al.  Normalization in the appearance of severly damaged psoriatic nails using soft x-rays. A case report. , 2007, Acta dermatovenerologica Croatica : ADC.

[99]  C. Vlachou,et al.  Nail psoriasis improvement in a patient treated with fumaric acid esters , 2007, The Journal of dermatological treatment.

[100]  C. Wilson,et al.  A case of nail psoriasis treated with topical calcitriol , 2006, Clinical and experimental dermatology.

[101]  P. V. D. van de Kerkhof,et al.  Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be? , 2006, Journal of the American Academy of Dermatology.

[102]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[103]  M. Sánchez Regaña,et al.  Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[104]  S. Chimenti,et al.  Remission and time of resolution of nail psoriasis during infliximab therapy. , 2005, Journal of the American Academy of Dermatology.

[105]  F. Aubin,et al.  Evaluation of a novel 308‐nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses , 2005, The British journal of dermatology.

[106]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[107]  N. Dalbeth,et al.  Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked. , 2004, Rheumatology.

[108]  S. Hsu,et al.  Serum sickness due to infliximab in a patient with psoriasis. , 2004, Journal of drugs in dermatology : JDD.

[109]  P. Amerio,et al.  Nail Psoriasis: Combined Therapy with Systemic Cyclosporin and Topical Calcipotriol , 2004 .

[110]  P. Bossuyt,et al.  The burden of psoriasis is not determined by disease severity only. , 2004, The journal of investigative dermatology. Symposium proceedings.

[111]  A. Björkman,et al.  Rupture of the extensor pollicis longus tendon: a study of aetiological factors , 2004, Scandinavian journal of plastic and reconstructive surgery and hand surgery.

[112]  A. Gottlieb,et al.  Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.

[113]  P. Bossuyt,et al.  Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. , 2003, The New England journal of medicine.

[114]  Richard K Scher,et al.  Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. , 2003, Journal of the American Academy of Dermatology.

[115]  S. Chimenti,et al.  Tazarotene 0·1% gel for psoriasis of the fingernails and toenails: an open, prospective study , 2003, The British journal of dermatology.

[116]  J. Szepietowski,et al.  Psoriatic Nails: A Prospective Clinical Study , 2003, Journal of cutaneous medicine and surgery.

[117]  F. Guarneri,et al.  Treatment of Psoriatic Nails with Topical Cyclosporin: A Prospective, Randomized Placebo-Controlled Study , 2003, Dermatology.

[118]  C. Antoni,et al.  Infliximab for psoriasis and psoriatic arthritis. , 2002, Clinical and experimental rheumatology.

[119]  J. Gulcher,et al.  HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. , 2002, The Journal of investigative dermatology.

[120]  M. Stiller,et al.  Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. , 2001, Cutis.

[121]  A. Finlay,et al.  Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin , 2001, The British journal of dermatology.

[122]  M. Lebwohl,et al.  The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. , 2001, Archives of dermatology.

[123]  E. D. De Jong,et al.  Dystrophic Psoriatic Fingernails Treated with 1% 5-Fluorouracil in a Nail Penetration-Enhancing Vehicle: A Double-Blind Study , 1999, Dermatology.

[124]  D M Reboussin,et al.  Psoriasis causes as much disability as other major medical diseases. , 1999, Journal of the American Academy of Dermatology.

[125]  Tosti,et al.  Calcipotriol ointment in nail psoriasis: a controlled double‐blind comparison with betamethasone dipropionate and salicylic acid , 1998, The British journal of dermatology.

[126]  Toshiyuki Yamamoto,et al.  Topical Anthralin Therapy for Refractory Nail Psoriasis , 1998, The Journal of dermatology.

[127]  Lawrence,et al.  A simplified protocol of steroid injection for psoriatic nail dystrophy , 1998, The British journal of dermatology.

[128]  D. Fortune,et al.  Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. , 1997, The British journal of dermatology.

[129]  A. Lassus.  Colloidal Silicic Acid for the Treatment of Psoriatic Skin Lesions, Arthropathy and Onychopathy. A Pilot Study , 1997, The Journal of international medical research.

[130]  T. Y. Kwang,et al.  A therapeutic study of nail psoriasis using electron beams. , 1995, Acta dermato-venereologica.

[131]  W. P. Arnold,et al.  Response of nail psoriasis to cyclosporin , 1993, The British journal of dermatology.

[132]  R. Yu,et al.  A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. , 1992, Acta dermato-venereologica.

[133]  R. Wolf,et al.  Corticosteroid-induced 'disappearing digit'. , 1990, Journal of the American Academy of Dermatology.

[134]  K. Fritz.  [Successful local treatment of nail psoriasis with 5-fluorouracil]. , 1989, Zeitschrift fur Hautkrankheiten.

[135]  D. Goette,et al.  Distal phalangeal atrophy secondary to topical steroid therapy. , 1987, Archives of dermatology.

[136]  J. Boyle,et al.  Local PUVA treatment for nail psoriasis , 1987, The British journal of dermatology.

[137]  R. Scher,et al.  Response of psoriatic nails to oral photochemotherapy. , 1980, Archives of dermatology.

[138]  R. Peachey,et al.  The treatment of psoriatic nail dystrophy with intradermal steroid injections , 1976, The British journal of dermatology.

[139]  T. Fredriksson.  Topically applied fluorouracil in the treatment of psoriatic nails. , 1974, Archives of dermatology.

[140]  J. Bleeker.  Intralesional triamcinolone acetonide using the Port‐O‐Jet and needle injections in localized dermatoses , 1974, The British journal of dermatology.

[141]  P. Samman,et al.  Intradermal triamcinolone treatment of nail dystrophies , 1973, The British journal of dermatology.

[142]  E. Feuerman,et al.  Allopurinol in psoriasis–a double‐blind study , 1973, The British journal of dermatology.

[143]  W. Gerstein.  Psoriasis and lichen planus of nalis. Treatment with triamcinolone. , 1962, Archives of dermatology.

[144]  M. Gooderham,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). , 2016, Journal of the American Academy of Dermatology.

[145]  L. Barreiro Pérez,et al.  [Nail psoriasis]. , 2014, Anales de pediatria.

[146]  L. Pescitelli,et al.  Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result , 2013, Dermatologic therapy.

[147]  M. Lebwohl,et al.  Interventions for nail psoriasis (Review) , 2013 .

[148]  F. Llambi,et al.  Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. , 2012, Actas dermo-sifiliograficas.

[149]  S. Lestre,et al.  Treatment of severe nail psoriasis with etanercept. , 2011, Indian journal of dermatology, venereology and leprology.

[150]  M. Gómez Vázquez,et al.  Marked improvement in nail psoriasis during treatment with etanercept , 2011, Dermatologic therapy.

[151]  G. Márquez Balbás,et al.  Tacalcitol ointment for the treatment of nail psoriasis. , 2009, The Journal of dermatological treatment.

[152]  B. Thiers.  Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study , 2009 .

[153]  André Reis,et al.  Psoriasis is associated with increased beta-defensin genomic copy number. , 2008, Nature genetics.

[154]  T. Tzung,et al.  Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. , 2008, Acta dermato-venereologica.

[155]  A. Gottlieb,et al.  A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. , 2007, Journal of the American Academy of Dermatology.

[156]  D. Rigopoulos,et al.  Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. , 2007, Acta dermato-venereologica.

[157]  H. Mortazavi,et al.  Topical calcipotriol therapy in nail psoriasis: a study of 24 cases. , 2005, Dermatology online journal.

[158]  D. Rigopoulos,et al.  Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. , 2002, Acta dermato-venereologica.

[159]  Y. Takagi,et al.  Nail lesions in psoriatic arthritis : recovery with sulfasalazine treatment , 2002 .

[160]  A. Tosti,et al.  Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation , 1999 .

[161]  L. Färber,et al.  Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. , 1995, Journal of the American Academy of Dermatology.

[162]  A. Tosti,et al.  Topical ciclosporin in nail psoriasis. , 1990, Dermatologica.

[163]  B. Lindelöf.  Psoriasis of the nails treated with grenz rays: a double-blind bilateral trial. , 1989, Acta dermato-venereologica.

[164]  N. Weiner,et al.  Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. , 1988, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[165]  J. Jakubík.  Finger tendon rupture following local application of triamcinolone-acetonide (Kenalog A-40). , 1981, Acta chirurgiae plasticae.

[166]  E. Finnerty.  Successful treatment of psoriasis of the nails. , 1979, Cutis.

[167]  Finnerty Ef.  Successful treatment of psoriasis of the nails. , 1979 .